Last reviewed · How we verify
Tricyclic antidepressants
At a glance
| Generic name | Tricyclic antidepressants |
|---|---|
| Also known as | antidepressant version medical dispositive |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments (PHASE2)
- Discontination of Antidepressants in Remitted Depression (PHASE4)
- Different Transcutaneous Electrical Nerve Stimulation Modes in Pudendal Neuralgia Post-prostatectomy (NA)
- Comparing Inflammatory Markers in Patients With and Without Depression With Chronic Periodontitis (NA)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive Disorder (NA)
- Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tricyclic antidepressants CI brief — competitive landscape report
- Tricyclic antidepressants updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI